As a veteran of the AWP litigation era, I am struck by the recent state efforts to legislate transparency into pharmaceutical pricing. Multiple states have introduced bills that would require pharmaceutical manufacturers to...more
8/26/2015
/ Attorney General ,
Disclosure Requirements ,
Drug Pricing ,
Fraud ,
Medicaid ,
Pending Legislation ,
Pharmaceutical Industry ,
Pharmacies ,
Transparency ,
Whistleblowers ,
Wholesale
The 340B Drug Discount Program has operated for more than 20 years with just a few governing regulations codified in 42 CFR Part 10. Through the Affordable Care Act (“ACA”), Congress adopted several amendments to the 340B...more